AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04695626 — intervention group
Intervention type: PROCEDURE
Intervention: The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)
Description: According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
Study NCT00324194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 oral dose given 2 times per week.
Study NCT01971593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eplerenone
Study NCT03501511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IDF modules
Description: Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
Study NCT03501511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational Maps
Description: Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
Study NCT00827463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dosage of the NFS and iron
Description: a blood test will be made.
Study NCT01719770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
Study NCT03745456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for ROTEM and platelet function.
Description: Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
Study NCT00806026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo and pregabalin
Description: following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
Study NCT00806026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexol
Description: following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Study NCT00806026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexol
Description: following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Study NCT00806026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Study NCT00806026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexol
Description: pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Study NCT00806026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexol
Description: pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Study NCT02241915 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Open Colorectal Surgery
Study NCT02241915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Colorectal Surgery
Study NCT02241915 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic Surgery
Study NCT02241915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Study NCT00104715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen therapy
Study NCT00104715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiandrogen therapy
Study NCT00104715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00104715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Study NCT00104715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate
Study NCT00104715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orchiectomy
Study NCT00104715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orchiectomy
Study NCT01653262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Study NCT04193215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: IM injection
Study NCT04193215 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pediatric vaccines
Description: Standard of care vaccines administered according to the local recommended schedule.
Study NCT04193215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric vaccines
Description: Standard of care vaccines administered according to the local recommended schedule.
Study NCT04757857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 mg
Description: Rivaroxaban pharmaceutical form will be tablets of 10 mg
Study NCT02583477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 in combination with nab-paclitaxel and gemcitabine
Description: MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
Study NCT00667277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: 15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
Study NCT02167477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Tracheal intubation
Study NCT02167477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz C-MAC, standard blade
Description: Tracheal intubation
Study NCT02167477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz C-MAC, D-BLADE
Description: Tracheal intubation
Study NCT01738399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Study NCT01738399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03550144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awe Walk
Description: To examine the effect of weekly awe walks in cognitively healthy older adults.
Study NCT03550144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Walk
Description: To examine the effect of weekly walks in cognitively healthy older adults.
Study NCT04379583 — intervention group
Intervention type: DEVICE
Intervention: HairDx Sample Collection Kit
Description: Saliva collection using FDA OTC cleared sample collection device
Study NCT03863938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: K-CAB
Study NCT00545818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ length 6 mm
Description: OsseoSpeed™ dental implant, length: 6 mm
Study NCT00545818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OsseoSpeed™ length 11 mm
Description: OsseoSpeed™ dental implant, length: 11 mm
Study NCT02489630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.1mg/kg ketamine IV
Study NCT02489630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1ml/kg normal saline placebo
Study NCT02489630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opiate analgesic
Description: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
Study NCT01719770 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
Study NCT00802763 — intervention group
Intervention type: DEVICE
Intervention: NORMA-SENSE
Description: Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
Study NCT02698579 — intervention group
Intervention type: GENETIC
Intervention: No interventional drug product utilized in this follow-up study
Description: Participants received a single IV infusion of Lenti-D Drug Product (also known as elivaldogene autotemcel or eli-cel) in either parent Study ALD-102 or ALD-104.~The objectives of this long-term follow-up study are to assess long-term safety and efficacy following completion of participation in parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant are conducted in this study.
Study NCT01822119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha Attract System
Study NCT02583477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 in combination with AZD5069
Description: MEDI4736 via IV infusion and oral AZD5069
Study NCT02904356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
Study NCT01428141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
Study NCT02169999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Diabetes Care Website
Description: Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
Study NCT02587364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 50 mg
Description: Gemcabene 50 mg once daily (QD)
Study NCT02587364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 150 mg
Description: Gemcabene 150 mg once daily (QD)
Study NCT02587364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 450 mg
Description: Gemcabene 450 mg once daily (QD)
Study NCT02489630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: opiate analgesic
Description: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
Study NCT02587364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 750/600 mg
Description: Gemcabene 750/600 mg once daily (QD)
Study NCT02587364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Description: Gemcabene 900 mg once daily (QD)
Study NCT02587364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily (QD)
Study NCT04993742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMS Intervention
Description: Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
Study NCT02521246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan + Chlorthalidone
Study NCT02521246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan+hydrochlorothiazide
Study NCT00861042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM927/Lacosamide
Description: SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
Study NCT02032875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT02032875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT02032875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT03676309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutriceutical Oral Capsule,
Description: nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
Study NCT03676309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
Study NCT05073289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sandplay activity
Description: The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
Study NCT05073289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
Study NCT03045380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game based physical activity training
Description: Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
Study NCT03045380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
Study NCT03985137 — intervention group
Intervention type: OTHER
Intervention: mucocutaneous sampling by swab at the balano-preputial furrow.
Description: the sample is made by the patient
Study NCT03385668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
Study NCT01100021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin and avanafil
Description: tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
Study NCT01100021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin and avanafil
Description: doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
Study NCT02729129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure with filtered facemask
Description: 1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
Study NCT02729129 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diesel exhaust exposure with sham mask
Description: 1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
Study NCT01981928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7962
Description: Oral
Study NCT01981928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03901209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mid-face osteotomy
Description: The mid-face osteotomy - typically according to LeFort I - is performed using a pulsed erbium-doped yttrium aluminium garnet (Er:YAG) laser driven by the CARLO robot arm.
Study NCT03175588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Rehabilitation
Description: Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
Study NCT01444170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dicreatinol sulfate
Description: nutritional supplement
Study NCT01444170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo sugar pill
Study NCT01444170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo sugar pill
Study NCT01666405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgent(R) PC Neuromodulation System
Description: The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
Study NCT02492776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg oral capsules administered once daily for 8 days
Study NCT02492776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
Study NCT02492776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
Study NCT01642966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg/day for 15 days
Study NCT01642966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice a day for 15 days
Study NCT02577120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiceram Skin Barrier Function
Description: Epiceram is a non-sterile, viscous, lipid-rich emulsion
Study NCT01091350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diprifusor (Target-controlled infusion)
Description: Two TCI devices with different Teo and same Marsh PK model
Study NCT00222261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Aspirin 160 mg once daily for two years
Study NCT00222261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 75 mg once daily for two years
Study NCT01131585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active laser photocoagulation
Description: Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
Study NCT01131585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active laser photocoagulation
Description: Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
Study NCT01091350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orchestra (Target-controlled infusion)
Description: Two TCI devices with different Teo and same Marsh PK model
Study NCT01483573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: stretch the nerve
Study NCT01483573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: straight leg raise
Description: stretch the hamstring
Study NCT01131585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham injections
Description: Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Study NCT01131585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Study NCT02577120 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline Petroleum Jelly
Description: A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
Study NCT03112850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aid
Description: LOF hearing aid
Study NCT03112850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Auditory Training